ImmunSYS is dedicated to developing therapeutics for several types of cancer.
In addition to prostate cancer, ImmunSYS is developing the platform YourVaccx™ technology for several other types of late stage cancer. Our pipeline includes five proprietary, highly novel product candidates currently in development. Our platform technology has a unique mechanism of action, and we believe that it could yield important therapeutic advances and differentiation from existing therapies for many metastatic cancers.
*”IMD110” is an experimental compound code name; the drug will ultimately be named via the FDA approval process.